GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IQVIA Holdings Inc (NYSE:IQV) » Definitions » PE Ratio without NRI

IQV (IQVIA Holdings) PE Ratio without NRI : 19.58 (As of Oct. 31, 2024)


View and export this data going back to 2013. Start your Free Trial

What is IQVIA Holdings PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2024-10-31), IQVIA Holdings's share price is $205.82. IQVIA Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was $10.51. Therefore, IQVIA Holdings's PE Ratio without NRI for today is 19.58.

During the past 13 years, IQVIA Holdings's highest PE Ratio without NRI was 113.98. The lowest was 17.33. And the median was 31.32.

IQVIA Holdings's EPS without NRI for the three months ended in Jun. 2024 was $2.64. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was $10.51.

As of today (2024-10-31), IQVIA Holdings's share price is $205.82. IQVIA Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $7.70. Therefore, IQVIA Holdings's PE Ratio (TTM) for today is 26.73.

Good Sign:

IQVIA Holdings Inc stock PE Ratio (=28.06) is close to 5-year low of 27.03

During the past years, IQVIA Holdings's highest PE Ratio (TTM) was 291.95. The lowest was 15.67. And the median was 36.86.

IQVIA Holdings's EPS (Diluted) for the three months ended in Jun. 2024 was $1.97. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $7.70.

IQVIA Holdings's EPS (Basic) for the three months ended in Jun. 2024 was $1.99. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was $7.81.


IQVIA Holdings PE Ratio without NRI Historical Data

The historical data trend for IQVIA Holdings's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IQVIA Holdings PE Ratio without NRI Chart

IQVIA Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 119.59 105.46 54.76 35.09 22.68

IQVIA Holdings Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.02 21.15 22.68 24.55 20.12

Competitive Comparison of IQVIA Holdings's PE Ratio without NRI

For the Diagnostics & Research subindustry, IQVIA Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IQVIA Holdings's PE Ratio without NRI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where IQVIA Holdings's PE Ratio without NRI falls into.



IQVIA Holdings PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

IQVIA Holdings's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=205.82/10.510
=19.58

IQVIA Holdings's Share Price of today is $205.82.
IQVIA Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.51.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


IQVIA Holdings  (NYSE:IQV) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


IQVIA Holdings PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of IQVIA Holdings's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


IQVIA Holdings Business Description

Traded in Other Exchanges
Address
2400 Ellis Road, Durham, NC, USA, 27703
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Executives
Eric Sherbet officer: See Remarks 100 IMS DRIVE, PARSIPPANY NJ 07054-4235
Ari Bousbib director, officer: Chairman, CEO & Pres UNITED TECHNOLOGIES CORP, ONE FINANCIAL PLAZA, HARTFORD CT 06101
W Richard Staub officer: See Remarks
Kevin C Knightly officer: Pres Info & Tech Solutions 1499 POST ROAD, FAIRFIELD CT 06824
Panagos Constantinos officer: See Remarks 4280 EMPEROR BLVD, DURHAM NC 27703
Keriann Cherofsky officer: See Remarks 4280 EMPEROR BLVD, DURHAM NC 27703
Sheila A Stamps director C/O CIT GROUP, 1 CIT DRIVE, ATTN: GENERAL COUNSEL, LIVINGSTON NJ 07039
Morris Leslie Wims director 4280 EMPEROR BLVD, DURHAM NC 27703
John Connaughton director, 10 percent owner BAIN CAPITAL PARTNERS LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Ronald E Bruehlman officer: See Remarks C/O IQVIA HOLDINGS, INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
Ronald A Rittenmeyer director 5400 LEGACY DRIVE, PLANO TX 75024
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Michael J Evanisko director BRAUN CONSULTING, 20 W KINZIE STREET SUITE 1600, CHICAGO IL 60610
Michael R Mcdonnell officer: Chief Financial Officer C/O IQVIA HOLDINGS INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
John M. Leonard director C/O INTELLIA THERAPEUTICS INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139